TARCEVA® 100 mg (Erlotinib hcl)
| Product Overview | |
| Generic Name | TARCEVA® 100 mg (Erlotinib hcl) |
| Brand Name(s) | TARCEVA® |
| Form | 30 Oral film-coated tablets / comprimidos |
| Strength | 100 mg |
| Therapeutic Class | EGFR tyrosine kinase inhibitor (protein kinase inhibitor) |
| ATC Code | L01EB02 |
| Manufacturing & Regulatory | |
| Manufacturer | Roche |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.5474.00 |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 1 Units |
| Shelf Life | 24 Months |
| Storage | Controlled room temperature 20–25 °C |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
Description
Erlotinib is an EGFR tyrosine kinase inhibitor indicated for specific cancers including EGFR mutation–positive non-small cell lung cancer (NSCLC); it is also used with gemcitabine for pancreatic cancer in certain settings
* This is the BRAND version TARCEVA® only.
